Date: 2017-04-19
Type of information: Clinical research agreement
Compound: TIL therapy - Tumor infiltrating lymphocytes therapy
Company: Lion Biotechnologies (USA - CA) The University of Texas MD Anderson Cancer Center (USA - TX)
Therapeutic area: Cancer - Oncology
Type agreement: clinical research
Action mechanism:
- cell therapy/immunotherapy product.
- Tumor infiltrating lymphocytes (TIL) have the capacity to recognize and attack the tumor traffic and infiltrate into the tumor. However, the anti-tumor effect of these cells is usually short-lived because cancer cells adapt and suppress the anti-tumor immune response through the release of various anti-inflammatory factors into the local environment. Here, TIL are first extracted from the patient and expanded in tissue culture with IL-2. Then the amplification process eliminates the immune-suppressive environment created by the tumor which is so effective at neutralizing the natural anti-tumor immune response. Third, this same culture environment optimizes the replication and activation of aggressive anti-tumor TIL. Once sufficient numbers of cells with the appropriate anti-tumor potential have been cultured, they are then re-administered back into the donor patient where they have been shown to mediate impressive anti-tumor responses.
Disease: ovarian cancer, sarcomas, pancreatic cancer
Details:
- • On April 19, 2017, Lion Biotechnologies and The University of Texas MD Anderson Cancer Center announced a multi-year strategic alliance agreement involving multi-arm clinical trials to evaluate the safety and efficacy of TIL therapy in ovarian cancer, various sarcomas, and pancreatic cancer. In addition, preclinical research will explore the expansion of TIL in other rare tumor types.
- In the clinical trials, TIL therapy will be evaluated in multiple solid tumor cancers using two different TIL manufacturing processes. The trials will be designed by the Lion and MD Anderson joint steering committee and conducted at MD Anderson. A related preclinical research collaboration will focus on the expansion of TIL from additional tumor types to identify new indications for future clinical research. Lion and MD Anderson will both have manufacturing responsibilities for production of TILs used in the planned cellular therapy trials.
Financial terms:
Latest news:
Is general: Yes
